当前位置：
X-MOL 学术
›
Ther. Adv. Med. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: a systematic review and meta-analysis
Therapeutic Advances in Medical Oncology ( IF 4.3 ) Pub Date : 2019-06-09 , DOI: 10.1177/1758835919855235 Yan-Li Yang 1 , Zi-Jian Xiang 2 , Jing-Hua Yang 2 , Wen-Jie Wang 2 , Ruo-Lan Xiang 3
Therapeutic Advances in Medical Oncology ( IF 4.3 ) Pub Date : 2019-06-09 , DOI: 10.1177/1758835919855235 Yan-Li Yang 1 , Zi-Jian Xiang 2 , Jing-Hua Yang 2 , Wen-Jie Wang 2 , Ruo-Lan Xiang 3
Affiliation
Breast cancer is the most common malignant cancer among women worldwide, in both developing and developed countries. The survival rate of breast cancer is highly correlated with the degree of disease at the time of diagnosis, with early stage disease conferring superior survival rates. However, the majority of patients with advanced breast cancer develop bone metastases.1 Some studies have reported that increased osteoclast activity in patients with breast cancer and breast cancer bone metastases leads to skeletal-related events (SREs), which include bone fractures, hypercalcemia, nerve compression, and severe pain.2 These skeletal complications, in turn, increase the need for palliative radiation or surgery to bone, limit functional independence, adversely affect quality of life, and continue to cause morbidity of the affected patients.3,4
更新日期：2019-06-09
京公网安备 11010802027423号